NOVARTIS INDIA Fundamental Trends Analysis

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NI</div>
NOVARTIND -- India Stock  

INR 562.25  4.85  0.86%

The Drivers Module shows relationships between NOVARTIS INDIA's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of NOVARTIS INDIA LTD over time as well as its relative position and ranking within its peers. Additionally, see Stocks Correlation

Search Current Fundamental Trends

 
Refresh

NOVARTIS INDIA LTD Earnings Per Share vs. Total Debt Fundamental Analysis

NOVARTIS INDIA LTD is rated top company in total debt category among related companies. It is considered to be number one stock in earnings per share category among related companies . The ratio of Total Debt to Earnings Per Share for NOVARTIS INDIA LTD is about  72,138,229 
NOVARTIS INDIA LTD is rated top company in total debt category among related companies. Total debt of Drug Manufacturers?Specialty & Generic industry is now estimated at about 1.34 Billion. NOVARTIS INDIA totals roughly 668 Million in total debt claiming about 50% of equities under Drug Manufacturers?Specialty & Generic industry.
Total debt  Workforce  Valuation  Capitalization  Revenue
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
NOVARTIS INDIA 
Total Debt 
 = 
Bonds 
+  
Notes 
=
668 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
NOVARTIS INDIA 
Earnings per Share 
 = 
Earnings 
Average Shares 
=
9.26 
Earnings per Share is one of the most critical measures of the current share price of a firm, and is used by investors to determine the overall company profitability; especially when it is compared to the EPS of similar companies.

NOVARTIS Earnings Per Share Comparison

NOVARTIS Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page